SILK

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ron BaronBaron Capital $-34.6M ExitQ3 2024 $35M -- $27.49
Ken GriffinCitadel Advisors $-8.9M ExitQ3 2024 $9M -- $27.49
Mario GabelliGAMCO Investors $-6.9M ExitQ3 2024 $7M -- $27.49
Jefferies GroupInvestor $-1.3M ExitQ3 2024 $1M -- $27.49
Paul Tudor Jones IITudor Investment $-610.8K ExitQ3 2024 $611k -- $27.49
Jim SimonsRenaissance Technologies $-13.1M ExitQ3 2024 $13M -- $27.49

Insider Trades

Name	Value	Action	Price	Current Price
Klemz Kevin MEVP/Chief Legal Officer/Sec. $61k2.3k shares SellAug 19, 2024 $27.10 $27.49

Trade SILK

About Silk Road Medical, Inc

Silk Road Medical, Inc. operates as an American medical device company, focusing on innovative solutions for carotid artery disease. The firm's product portfolio is specifically engineered to support transcarotid artery revascularization (TCAR) procedures. Among its key offerings is the ENROUTE Transcarotid Neuroprotection System, designed to directly access the common carotid artery and initiate a temporary reversal of blood flow. The company also provides the ENROUTE Transcarotid Stent System, a distinctive stent characterized by its self-expanding and self-tapering capabilities. For streamlined initial entry to the common carotid artery, Silk Road Medical offers the ENHANCE Transcarotid Peripheral Access Kit. Additionally, the ENROUTE 0.014 Guidewire plays a crucial role in navigating and crossing target lesions, enabling the precise delivery of other interventional devices. Founded in 2007, Silk Road Medical, Inc. maintains its primary corporate offices in Sunnyvale, California.

CEO: Charles S. McKhann
IPO Date: Apr 4, 2019

Market Data

Open: $27.49
High: $27.50
Low: $27.49
Volume: 2.3M
Avg Volume: 1.1M
52W High: $27.51
52W Low: $6.08

Valuation

Market Cap: $1.1B
Enterprise Value: $1.2B
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$33.5M
Revenue: $177.1M
Net Income: -$55.7M
Cash: $20.2M
Debt: $84.6M

Events

EarningsAug 7

EPS est. -0.38 · actual -0.42